OCT 10, 2019 12:00 PM PDT

Tumor Mutation Burden: Challenges and opportunities of measuring and interpreting tumor mutational burden for patient care

Sponsored by: QIAGEN
Speaker

Abstract

Tumor mutational burden (TMB) is an emerging biomarker that correlates with response to immunotherapeutic agents, such as checkpoint inhibitors. Recent studies indicate that a high mutation load increases the likelihood that immunogenic neoantigens expressed by tumor cells may induce a response to immunotherapy.  However, TMB estimation and reporting can be heavily influenced by differing working processes across clinical and research laboratories; primarily, the choice of assay, platform, and how the assay is implemented and interpreted. To streamline and standardize this process at scale, QIAGEN offers an end to end solution, from detection to interpretation of TMB and other somatic alterations.

In this webinar, we will provide insights into the implementation of the QIAseq Tumor Mutational Burden (TMB) Panel in the molecular diagnostics lab. This comprehensive cancer panel is capable of interrogating TMB, microsatellite instability (MSI), and other actionable alterations in a single assay, using specialized chemistry to remove false positives. Subsequently, we will discuss how QIAGEN Clinical Insight Interpret can streamline insights from comprehensive cancer profiles to deliver actionable information on detected variants and immunotherapy biomarkers, such as tumor mutational burden (TMB) and microsatellite instability (MSI). We will also discuss the concordance of the automatic implementation of the AMP/ASCO/CAP guidelines with manual expert classifications.


Show Resources
You May Also Like
MAY 11, 2021 10:00 AM PDT
C.E. CREDITS
MAY 11, 2021 10:00 AM PDT
Date: May 11, 2021 Time: 10:00zm PDT Your samples are some of the most valuable assets in the laboratory. After spending countless hours on extraction and preparation, your conclusions could...
SEP 14, 2021 7:00 AM PDT
C.E. CREDITS
SEP 14, 2021 7:00 AM PDT
Date: September 14, 2021 Time: 7am PDT, 10am EDT, 4pm CEST A conventional thermal cycler has long been a commodity product in the lab and end-point PCR techniques can be completed almost wit...
JUN 09, 2021 7:00 AM PDT
C.E. CREDITS
JUN 09, 2021 7:00 AM PDT
Date: June 9, 2021 Time: 09 June 2021, 7am PDT, 10am EDT, 4pm CEST cells with dramatic implications on the validity of past cell culture related research. The fact that at least 509 cell lin...
JUL 15, 2021 8:00 AM PDT
C.E. CREDITS
JUL 15, 2021 8:00 AM PDT
Date: July 15, 2021 Time: 8:00am (PDT), 11:00am (EDT) High dimensional full spectrum flow cytometry grants unprecedented access to previously unattainable parameters in cellular biology. Flu...
OCT 20, 2021 10:00 AM PDT
C.E. CREDITS
OCT 20, 2021 10:00 AM PDT
Date: October 20, 2021 Time:10:00am (PDT), 1:00pm (EDT) As the prevalence of Diabetes continues to rise in many areas across the globe, healthcare providers continue to look for methods that...
NOV 17, 2021 8:00 AM PST
C.E. CREDITS
NOV 17, 2021 8:00 AM PST
Date: November 17, 2021 Time: 8:00am (PDT), 11:00am (EDT) From waste disposal to promising biomarkers and therapeutic agents, exosomes and other extracellular vesicles are valuable in resear...
OCT 10, 2019 12:00 PM PDT

Tumor Mutation Burden: Challenges and opportunities of measuring and interpreting tumor mutational burden for patient care

Sponsored by: QIAGEN

Specialty

Cancer

Immunology

Molecular Biology

Cancer Research

Cancer Diagnostics

Clinical Diagnostics

Dna

Molecular Diagnostics

Biomarkers

Diagnostics

Tumor

Antibodies

Laboratory Testing

Cancer Therapeutics

Gene Expression

Geography

Asia60%

North America20%

Europe13%

Africa7%

Registration Source

Website Visitors100%

Job Title

Student25%

Clinical Laboratory Scientist25%

Educator/Faculty17%

Research Scientist17%

Facility/Department Manager8%

Biologist8%

Organization

Academic Institution53%

Life Science Company13%

Diagnostic Company7%

Consultant7%

Clinical Laboratory7%

Independent Laboratories7%

Government7%


Show Resources
Loading Comments...
Show Resources